DBV Technologies (NASDAQ:DBVT) Releases Earnings Results, Misses Estimates By $4.24 EPS

DBV Technologies (NASDAQ:DBVT) issued its earnings results on Thursday. The company reported ($4.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($4.24), FiscalAI reports. DBV Technologies had a negative net margin of 2,273.91% and a negative return on equity of 295.58%.

DBV Technologies Price Performance

Shares of DBV Technologies stock traded down $0.06 on Thursday, hitting $20.21. 200,324 shares of the company’s stock traded hands, compared to its average volume of 345,987. The company has a fifty day moving average of $21.57 and a two-hundred day moving average of $17.12. DBV Technologies has a one year low of $3.91 and a one year high of $26.18. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -3.91 and a beta of -0.97.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors have recently made changes to their positions in DBVT. MPM Bioimpact LLC bought a new position in DBV Technologies during the second quarter valued at about $9,649,000. Adage Capital Partners GP L.L.C. bought a new stake in DBV Technologies in the second quarter worth about $9,659,000. Octagon Capital Advisors LP bought a new stake in DBV Technologies in the second quarter worth about $9,315,000. Two Sigma Investments LP purchased a new position in DBV Technologies in the third quarter valued at about $167,000. Finally, Citadel Advisors LLC purchased a new position in DBV Technologies in the third quarter valued at about $220,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. HC Wainwright set a $40.00 price objective on DBV Technologies in a research note on Thursday, December 18th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Citizens Jmp upped their price objective on shares of DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday, December 17th. Wall Street Zen upgraded DBV Technologies from a “sell” rating to a “hold” rating in a research report on Sunday, February 8th. Finally, Cantor Fitzgerald set a $48.00 price target on DBV Technologies in a research note on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $38.25.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.